We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Fast Diagnosis of Infections Affecting Women

By HospiMedica staff writers
Posted on 07 Jul 2006
A range of new products have been developed to provide fast and efficient diagnosis of women's infections.

Inverness Medical Professional Diagnostics (Princeton, NJ, USA) developed these products, utilizing optical immunoassay (OIA) technology. More...
The BioStar OIA technology permits direct visual detection of the physical change in optical thickness of molecular thin films resulting from the binding reactions between antibodies and antigens. The signal is generated by the change in the reflection of light through the molecular thin films formed on an optical substrate.

White light reflected through the molecular thin film results in a predominant visual background gold color. Changes in the thickness of the optical molecular thin film will alter this gold color. The change occurs when antigens in liquid samples bind with immobilized antibodies. Because this binding reaction increases the thickness of the film, it changes the optical path through it and the gold color changes to blue or purple, indicating a positive result.

The BioStar OIA Streptococcus B test is a simple, rapid diagnostic test that provides results in just 21 minutes and helps monitor mothers during labor and delivery. The test identifies mothers at risk of delivering a group B Streptococcus (GBS) baby directly from cervical or vaginal swabs. This allows time for adequate prevention measures to be commenced, such as antibiotics during delivery, which reduces transmission of GBS from mother to child.

Timing is also the key to tackling chlamydia because one in four patients diagnosed with the disease do not return for follow-up treatment. Rapid diagnosis is vital as treatment delays of as little as three days from the onset of symptoms can result in infertility and/or ectopic pregnancies. A BioStar OIA Chlamydia test meets this need.

The BioStar OIA GC test is a rapid assay for the diagnosis of gonorrhea. BioStar OIA GC is a specific, rapid test for the detection of Neisseria gonorrhoeae (GC) from an endocervical swab for females or from male urine specimens. The BioStar OIA range of tests is designed for use by healthcare professionals in hospitals, clinics, laboratories, and other point-of-care settings.


Related Links:
Inverness Medical Professional Diagnostics

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Digital Radiography System (Ceiling Free)
Digix CF Series
Vessel Sealing Instrument
ERGOseal
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.